| Target Molecule | Terlipressin |
| Synonyms | Glypressin, Remestyp, Terlivaz, TGLVP, triglycyl lysine vasopressin |
| CAS Number | 14636-12-5 (free base / peptide); 1884420-36-3 (diacetate salt) |
| Sequence (3-Letter) | H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH₂ (cyclic Cys4–Cys9 disulfide) |
| Sequence (1-Letter) | GGGCYFQNCPKG-NH₂ (disulfide Cys4–Cys9) |
| Molecular Formula | C₅₂H₇₄N₁₆O₁₅S₂ (free base) |
| Molecular Weight | 1227.37 (free base) |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥98%, ≥99% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Directed Oxidative Folding |
| Modification Options | N-terminal triglycyl extension, intramolecular disulfide bridging, stable isotope labeling (13C, 15N), deletion impurity standards (diglycyl/monoglycyl variants) |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and disulfide connectivity verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Terlipressin (CAS 14636-12-5) is a synthetic 12-residue prodrug analogue of lysine vasopressin featuring an N-terminal triglycyl extension and a Cys4–Cys9 intramolecular disulfide bridge (H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH₂). We target this sequence to supply high-purity reference materials and raw materials for hepatorenal syndrome and vasoactive research.
Assembling three consecutive N-terminal glycines increases the risk of back-folding and aggregation during solid-phase peptide synthesis (SPPS). Our platform utilizes optimized coupling cocktails and precise temperature control, followed by directed oxidative folding to form the Cys4–Cys9 disulfide ring without polymerization.
Yes. We provide specialized peptide modification services for vasopressin prodrugs. Options include the synthesis of truncated deletion impurities (such as diglycyl and monoglycyl variants) as critical reference standards, site-specific stable isotope labeling (13C, 15N) for LC-MS/MS, and fluorescent tagging.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, disulfide verification, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development pipelines.
Terlipressin (CAS 14636-12-5), historically known as Glypressin, is a synthetic 12-amino-acid prodrug analogue of lysine vasopressin operating as a long-acting vasoactive agent. Defined by the sequence H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH₂ with an intramolecular Cys4–Cys9 disulfide bridge, it releases active lysine vasopressin via enzymatic cleavage in vivo. Synpeptide provides comprehensive custom synthesis solutions for this target molecule, demonstrating our technical expertise in poly-glycine assembly, directed disulfide cyclization, and CDMO manufacturing.
Constructing Terlipressin requires precise chain elongation of an N-terminal triglycyl stretch, which is inherently prone to hydrogen-bond-mediated aggregation on-resin. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols, elevated-temperature coupling cycles, and tailored deprotection monitoring. This approach prevents deletion sequences and ensures high-yield assembly of the 12-residue backbone.
Controlling N-terminal extension efficiency is vital, as incomplete coupling yields truncated diglycyl or monoglycyl impurities that mimic the active drug. Through our peptide modification services, we synthesize these specific deletion analogues as mandatory reference standards for stability-indicating assays. We also provide stable isotope labeling (13C, 15N) for pharmacokinetic bioanalysis and ensure exact verification of the Cys4–Cys9 disulfide ring.
Transitioning a cyclic, extended peptide from exploratory R&D to commercial scale demands robust downstream process engineering. High-dilution conditions required during oxidative folding prevent intermolecular oligomerization. We execute large-scale peptide synthesis for Terlipressin utilizing continuous-flow oxidation systems and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (consistently achieving the pharmaceutical acetate salt form) across all production volumes.
We deliver comprehensive technical support as a fully integrated peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete analytical documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
